超声 tight control 监测不同生物制剂治疗克罗恩病肠壁活动改善的多中心研究
结果显示BUS可监测生物制剂诱导的肠壁活动改善,12个月透壁愈合率为27.5%,基线肠壁增厚与较低透壁愈合风险相关。
要点
- BUS可用于监测克罗恩病患者生物制剂治疗后的肠壁活动改善与透壁愈合。
- 12个月透壁愈合率为27.5%,NNT为3.6,不同生物制剂间数值有差异。
- 基线肠壁增厚越大,3个月和12个月透壁愈合风险越低。
核心结论
- BUS有助于监测生物制剂诱导的克罗恩病肠壁活动改善与缓解。
主要发现
- 12个月透壁愈合率为27.5%,NNT为3.6;阿达木单抗后为26.8%,英夫利西单抗后为37%,维得利珠单抗后为27.2%,乌司奴单抗后为20%。
- 平均肠壁厚度较基线改善在3个月和12个月均有统计学意义(P < .0001)。
- 中位Harvey-Bradshaw指数、C反应蛋白和粪钙卫蛋白在12个月时较基线下降(P < .0001)。
- 逻辑回归显示基线肠壁厚度较大与3个月透壁愈合风险较低相关(P = .03,OR 0.70,95% CI 0.50-0.97),与12个月透壁愈合风险较低相关(P = .01,OR 0.58,95% CI 0.38-0.89)。
临床怎么用
- 临床可采用BUS参数(肠壁厚度、病变长度、回声模式、血流及透壁愈合)纵向监测生物制剂疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Bowel ultrasonography (BUS) is a noninvasive tool for evaluating bowel activity in Crohn's disease (CD) patients. Aim of our multicenter study was to assess whether BUS helps to monitor intestinal activity improvement/resolution following different biological therapies. METHODS: Adult CD patients were prospectively enrolled at 16 sites in Italy. Changes in BUS parameters [i.e. bowel wall thickening (BWT), lesion length, echo pattern, blood flow changes and transmural healing (TH: normalization of all BUS parameters)] were analyzed at baseline and after 3, 6 and 12 months of different biological therapies. RESULTS: One hundred eighty-eight out of 201 CD patients were enrolled and analyzed (116 males [62%]; median age 36 years). Fifty-five percent of patients were treated with adalimumab, 16% with infliximab, 13% with vedolizumab and 16% with ustekinumab. TH rates at 12 months were 27.5% with an NNT of 3.6. TH at 12 months after adalimumab was 26.8%, 37% after infliximab, 27.2% after vedolizumab and 20% after ustekinumab. Mean BWT improvement from baseline was statistically significant at 3 and 12 months (P < .0001). Median Harvey-Bradshaw index, C-reactive protein and fecal calprotectin decreased after 12 months from baseline (P < .0001). Logistic regression analysis showed colonic lesion was associated with a higher risk of TH at 3 months and a greater BWT at baseline was associated with a lower risk of TH at 3 months [P = .03 (OR 0.70, 95% CI 0.50-0.97)] and 12 months [P = .01 (OR 0.58, 95% CI 0.38-0.89)]. At 3 months therapy optimization during the study was the only independent factor associated with a higher risk of no ultrasonographic response [P = .02 (OR 3.34, 95% CI 1.18-9.47)] and at 12 months disease duration [P = .02 (OR 3.03, 95% CI 1.15-7.94)]. CONCLUSIONS: Data indicate that BUS is useful to monitor biologics-induced bowel activity improvement/resolution in CD.
引用
- Calabrese E, Rispo A, Zorzi F, et al. Ultrasonography Tight Control and Monitoring in Crohn's Disease During Different Biological Therapies: A Multicenter Study. Clin Gastroenterol Hepatol. 2021. PMID: 33775896. doi:10.1016/j.cgh.2021.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。